New research presented at AAOMS 2016 shows EXPAREL is safe and effective for pain relief following removal of wisdom teeth
PARSIPPANY, N.J., Sept. 21, 2016 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced new data regarding the benefit of EXPAREL® (bupivacaine liposome injectable suspension) for patients undergoing third molar (wisdom teeth) extraction, marking the official launch of the product to the oral surgeon community. EXPAREL is a local analgesic that provides prolonged non-opioid postsurgical pain control.
Taipei City Friday, October 21, 2016, Taiwan Liposome Company (TLC) announced that product candidate TLC178 has been granted an orphan drug designation for the treatment of cutaneous T-cell lymphoma (CTCL) by the US Food and Drug Administration (FDA). Lymphoma is the most common blood cancer. The two main forms of lymphoma are Hodgkin’s lymphoma and non-Hodgkin’s lymphoma (NHL). T-cell lymphomas account for approximately 15 percent of all cases of NHL in the US, with cutaneous T-cell lymphoma being one of the most common forms of T-cell lymphoma.
MENAFN Press - 21/09/2016 (MENAFN Press)